Kindred Biosciences Profit Margin

The latest profit margin for KIN is -550.38% as of June 2021. That compares with -70.56% in the prior-year period — down 680.0% year over year. That is below the Healthcare sector average of 21.34%. Investors often review this figure alongside Kindred Biosciences's historical trend and sector peers before judging valuation or financial health.

Over the past year, KIN's profit margin moved from -70.56% to -550.38% — a 680.0% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Kindred Biosciences's valuation or profitability profile.

Against Healthcare companies, KIN currently prints -550.38% for profit margin, while the sector average sits near 21.34%. That is roughly 2679.7% below the sector mean. Large gaps often invite a closer look at Kindred Biosciences's growth, margins, and balance sheet.

Profit Margin shows how effectively Kindred Biosciences converts resources into returns. At -550.38%, KIN may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -70.56% in the prior-year period — down 680.0% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting KIN's profit margin (-550.38%), review year-over-year change from -70.56%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.